Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Denali Therapeutics Inc (NASDAQ: DNLI) closed the day trading at $17.37 down -1.14% from the previous closing price of $17.57. In other words, the price has decreased by -$1.14 from its previous closing price. On the day, 3.0 million shares were traded. DNLI stock price reached its highest trading level at $17.76 during the session, while it also had its lowest trading level at $17.2.
Ratios:
For a better understanding of DNLI, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.79 and its Current Ratio is at 9.79. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 04 ’25 when CAROLE HO bought 1,882 shares for $19.00 per share.
Schuth Alexander O. sold 2,937 shares of DNLI for $39,884 on Aug 12 ’25. The COFO and Secretary now owns 242,346 shares after completing the transaction at $13.58 per share. On Aug 12 ’25, another insider, Ho Carole, who serves as the Chief Medical Officer of the company, sold 2,937 shares for $13.58 each. As a result, the insider received 39,884 and left with 217,391 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNLI now has a Market Capitalization of 2712471040 and an Enterprise Value of 1743792000.
Stock Price History:
The Beta on a monthly basis for DNLI is 1.04, which has changed by -0.24379623 over the last 52 weeks, in comparison to a change of 0.14045572 over the same period for the S&P500. Over the past 52 weeks, DNLI has reached a high of $24.68, while it has fallen to a 52-week low of $10.57. The 50-Day Moving Average of the stock is 2.79%, while the 200-Day Moving Average is calculated to be 15.69%.
Shares Statistics:
Over the past 3-months, DNLI traded about 1.79M shares per day on average, while over the past 10 days, DNLI traded about 2178490 shares per day. A total of 146.63M shares are outstanding, with a floating share count of 130.46M. Insiders hold about 11.05% of the company’s shares, while institutions hold 95.03% stake in the company. Shares short for DNLI as of 1764288000 were 12977218 with a Short Ratio of 7.27, compared to 1761868800 on 13110288. Therefore, it implies a Short% of Shares Outstanding of 12977218 and a Short% of Float of 9.9.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 14.0 analysts currently analyzing and rating the stock of Denali Therapeutics Inc (DNLI).The consensus estimate for the next quarter is -$0.77, with high estimates of -$0.73 and low estimates of -$0.82.
Analysts are recommending an EPS of between -$2.86 and -$3.33 for the fiscal current year, implying an average EPS of -$3.01. EPS for the following year is -$2.97, with 13.0 analysts recommending between -$1.94 and -$3.69.
